Greg P. Bertenshaw
Directeur des opérations chez BioMarker Strategies LLC
Profil
Greg P.
Bertenshaw is currently the Chief Operating & Science Officer at BioMarker Strategies LLC since 2020.
Previously, he worked as a Director at Clearant, Inc. from 2002 to 2004 and as a Technology Director at Correlogic Systems, Inc. from 2011 to 2013.
He completed his undergraduate degree at The University of Manchester and holds a doctorate degree from The Pennsylvania State University.
Postes actifs de Greg P. Bertenshaw
| Sociétés | Poste | Début |
|---|---|---|
BioMarker Strategies LLC
 BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD. | Directeur des opérations | 05/06/2020 |
Anciens postes connus de Greg P. Bertenshaw
| Sociétés | Poste | Fin |
|---|---|---|
Correlogic Systems, Inc.
 Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | Directeur Technique/Scientifique/R&D | 07/02/2013 |
Clearant, Inc.
 Clearant, Inc. Pharmaceuticals: MajorHealth Technology Clearant, Inc. produces tissue allograft implants, plasma therapies, blood and recombinant products. The company was founded on April 30, 1999 and is headquartered in Orlando, FL. | Directeur/Membre du Conseil | 02/01/2004 |
Formation de Greg P. Bertenshaw
| The University of Manchester | Undergraduate Degree |
| The Pennsylvania State University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Correlogic Systems, Inc.
Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | Health Technology |
Clearant, Inc.
Clearant, Inc. Pharmaceuticals: MajorHealth Technology Clearant, Inc. produces tissue allograft implants, plasma therapies, blood and recombinant products. The company was founded on April 30, 1999 and is headquartered in Orlando, FL. | Health Technology |
BioMarker Strategies LLC
BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD. | Health Technology |
